Hybridomas in biotechnology and medicine

Journal ofImmunologicaIMethods,

230

85 (1985) 230 Elsevier

JIM03745

Announcement

Hybridomas in Biotechnology and Medicine B o s t o n , M A , U.S.A., M a r c h 3 - 7 , 1986

Organizers T.A. Springer, Ph.D., S.J. Burakoff, M.D. and E.L. Reinherz, M.D.

Sponsored by Dana-Farber Cancer Institute, Harvard Medical School This course is designed for scientific investigators interested in the latest innovations and implications of immunology and hybridoma technology. Monoclonal antibodies and T cell lines are extraordinarily specific and powerful reagents which have opened up new avenues of investigation in clinical medicine, biotechnology, and diverse biological disciplines. A distinguished faculty will review the relevant basic immunology, and highlight the major advances achieved by application of this new technology. A comprehensive syllabus including selected methods protocols will be provided. The course is divided into 5 sections: (1) Antibody diversity and monoclonal antibodies; (2) Applications of monoclonal antibodies in basic biomedical research; (3) Monoclonal antibodies in diagnosis and therapy; (4) Uses of antibodies in recombinant DNA technology; and (5) T cell clones, hybridomas, and their products. To register and for additional information, write to: Harvard Medical School, Department of Continuing Education, Boston, MA 02115, U.S.A., or call: 617-732-1525 from 10 a.m. to 4 p.m.

0022-1759/85/$03.30 @ 1985 Elsevier Science Publishers B.V. (Biomedical Division)